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Abstract 6 
It has become increasingly clear that changes in metabolism are not just 7 
consequences of T cell activation but rather are essential drivers of that process, 8 
shaping the extent and nature of differentiation and function. The process of T 9 
cell exhaustion has been linked to the outcome of chronic immune responses in 10 
multiple contexts including chronic infection, cancer and autoimmunity. Factors 11 
regulating the development and maintenance of exhaustion are of increasing 12 
interest as the target of therapeutic modulation. Recent work has shown T cell 13 
immunometabolism to be integral to the control and development of T cell 14 
exhaustion. Early metabolic changes are responsible for later emergence of 15 
exhaustion, do not simply reflect changes secondary to chronic activation and 16 
are modifiable. An increased understanding of this metabolic control promises to 17 
improve our ability to modulate T cell immunity to chronic antigen stimulation 18 
in multiple contexts. 19 
 20 
Introduction 21 
The ability to sustain T cell function despite persisting antigen stimulation 22 
contributes to the clearance of both chronic infection and cancer. However, 23 
where T cell immunity targets self antigen or excessively damages healthy tissue, 24 
maintaining robust responses can prove harmful rather than helpful. T cell 25 
exhaustion has emerged as a key mechanism through which CD8 T cells lose 26 
effector capacity during persistent stimulation, curtailing their ability to cause 27 
damaging immunopathology but also facilitating viral persistence or hindering 28 
tumour-targeted responses. A substantial body of work using murine models of 29 
chronic LCMV virus infection has identified the molecular, transcriptional and 30 
functional basis of T cell exhaustion. Recent studies have implicated early 31 
metabolic signalling during T cell activation in the later development of 32 
exhaustion. In doing so this work has highlighted the potential for metabolic 33 
signals to shape T cell differentiation, and has focussed attention on the potential 34 
of immunometabolic therapies in multiple contexts. 35 
 36 
T cell differentiation and metabolism 37 
The process of T cell activation and differentiation involves rapid proliferation, 38 
cytokine production and development of cytotoxic effector function. For this to 39 
happen, cells must balance increasing energy demands with an increasing need 40 
for substrates to allow growth and division. Bioenergetic needs of naïve or 41 
quiescent T cells are primarily met by mitochondrial oxidative phosphorylation 42 
(OXPHOS), an efficient means of generating ATP from a glucose substrate1. On 43 
activation, however, there is a switch to aerobic glycolysis2 known as the 44 
‘Warburg effect’, a comparatively inefficient process in which fewer ATP 45 
molecules are generated per molecule of glucose processed3. A T cells choice of 46 
aerobic glycolysis initially makes little sense as it is not only inefficient, but 47 
seemingly unnecessary – cells switch to glycolysis even when abundant oxygen 48 
is available. However, the trade off is that a greater number of metabolic 49 
intermediates are produced for anabolic growth, including those for nucleotide 50 
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and amino acid synthesis4, maintenance of cellular redox balance 51 
(NAD+/NADH)5 and acetyl-CoA production for lipid synthesis through citrate 52 
processing6. The switch to aerobic glycolysis is also required for the 53 
development of full effector function (IL-2 and IFN- release), as the glycolytic 54 
enzyme GAPDH otherwise restricts translation of IFN- mRNA2.  55 
However, effector differentiation is not the only goal of T cell activation and the 56 
switch to aerobic glycolysis is not complete2. Following antigen encounter and 57 
eradication an expanded, persistent population of memory T cells shows a faster, 58 
more robust response to subsequent activation (Fig. 1). For such memory to 59 
develop during a primary T cell burst, aerobic glycolysis-driven effector function 60 
must be balanced with other metabolic pathways including OXPHOS7 and fatty 61 
acid oxidation (FAO)8,9. A central role for mitochondria in this balance has been 62 
highlighted by marked dynamic changes in their ultrastructure: Tmem show 63 
fusion of mitochondrial cristae into networks whereas their Teff counterparts 64 
undergo fission and remain expanded10. The mature memory phenotype is also 65 
fuelled by an increased mitochondrial biomass11 and spare respiratory capacity 66 
(SRC), driven by IL-15-mediated upregulation of carnitine palmitoyltransferase 67 
(CPT1a)7. CPT1a activity controls miotochondrial FAO and fosters the ability to 68 
generate a stronger, longer burst of both aerobic glycolysis and OXPHOS on 69 
restimulation11. However, it should be noted that the role of FAO has been 70 
demonstrated using pharmacological inhibition of CPT1a, the specificity of which 71 
has been brought into question by recent genetic deletion studies12. Much 72 
complexity surrounding the role of FAO in T cell differentiation remains to be 73 
unpicked.  74 
 75 
FIGURE 1 Balance between Teff/Tmem and metabolic pathways associated 76 
  77 
It is to be expected that dynamic metabolic changes must occur to keep pace with 78 
the rapid changes in cellular function that accompany T cell activation13. 79 
However, these studies have together implicated cellular metabolism – and 80 
mitochondrial biomass and function in particular - as a key driver of T cell 81 
phenotype, rather than simply reflecting changes in energy demand during 82 
differentiation8,14. With immunometabolism taking centre stage, it has now 83 
become clear that the development and maintenance of T cell exhaustion are also 84 
under metabolic regulation. 85 
 86 
Exhaustion and metabolism 87 
T cell exhaustion is associated with progressive dysfunction characterised by 88 
limited proliferation, cytokine production and effector capacity that is driven by 89 
persistent, high levels of antigen exposure and a relative lack of costimulatory 90 
‘help’ signals15. Exhaustion was originally identified in the murine LCMV model 91 
of chronic viral infection but has since been identified during numerous other 92 
chronic infections, in the tumour microenvironment and during 93 
autoinflammatory responses16,17. Its development controls persistence and 94 
outcome of cellular immunity to persistent antigen and has been associated with 95 
disease outcome in each case15,17. More recent work has demonstrated that 96 
exhaustion is also associated with significant bioenergtic compromise in the 97 
setting of both chronic viral infection and the tumour microenvironment18-20. 98 
The observed metabolic dysfunction precedes the development of exhaustion per 99 
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se and has been mechanistically linked to early inhibitory PD1 signals. However, 100 
this is only one part of a complex cascade modulating metabolism and the 101 
balance of effector function, cellular survival and exhaustion. To date, studies 102 
have focussed on catabolic metabolism, mitochondrial function and on pathways 103 
controlling them. Consequently, this review is similarly focussed, but this should 104 
not be taken to preclude the potential for downstream synthetic pathways to 105 
also play an important role.   106 
 107 
In the LCMV model of chronic viral infection, late emergence of T cell dysfunction 108 
is preceded by both transcriptional and functional changes suggesting glucose 109 
deprivation, with suppression of both glycolysis and OXPHOS18,21. Glucose 110 
transport is limited in early exhaustion with downregulation of GLUT1-mediated 111 
transport. However, alterations in glucose uptake were seen to be modest, 112 
prompting a search for changes in mitochondrial mass and function. This showed 113 
that mitochondria of exhausted cells (Texh) are larger, but dysfunctional. 114 
Increased mitochondrial biomass was accompanied by a paradoxical reduction 115 
in mitochondrial function (Oxygen consumption rate, OCR) and by increases in 116 
both mitochondrial depolarisation and reactive oxygen species (ROS) production 117 
relative to their effector counterparts (Teff). Ultrastructural changes in the 118 
mitochondria, including elongation of cristae, were also apparent18 although it is 119 
less clear how these relate to ultrastructural changes already known to 120 
differentiate classic memory and effector cell populations10. It is challenging – 121 
particularly in vivo - to quantify the degree of metabolic switching required to 122 
induce these mitochondrial changes (as it is with associated parameters such as 123 
spare respiratory capacity (SRC))7, and thus to understand their importance.in 124 
directing T cell fate. 125 
CD8+ tumour-infiltrating lymphocytes (TIL) also exhibit an exhausted 126 
phenotype22,23 that limits anti-tumour responses, and can be reversed by cancer 127 
immunotherapy with impressive results16.  Like Texh in chronic LCMV infection, 128 
TIL exhaustion in multiple murine models shows evidence of glucose deprivation 129 
and mitochondrial dysfunction. As in Texh in the LCMV model, reduced TIL 130 
glucose uptake was matched by reduced mitochondrial function (OCR) and 131 
increased depolarisation19,20. However, while bioenergetic changes of Texh were 132 
broadly similar in both TIL and chronic viral models, there were also differences. 133 
Whereas Texh in LCMV infection showed greater mitochondrial biomass and 134 
increased ROS production18, TILs showed a reduction in both19.  The apparent 135 
contribution of PD1 signaling to metabolic dysfunction was also different in the 136 
two contexts. Early metabolic dysfunction of Texh in LCMV-cl13 infection 137 
responded to either genetic deletion of PD1 (adoptive transfer of transgenic 138 
Pdcd1-/- LCMV-specific P14 T cells) or to PDL1 blockade18,19. However, 139 
mitochondrial biomass was not substantially altered by PD1 blockade in TILs, 140 
even though the blockade resulted in effective tumour regression19. These 141 
context-specific differences in metabolic features of exhaustion require further 142 
investigation but some explanations can be offered based on our increasing 143 
appreciation of metabolic factors controlling T cell effector function, survival and 144 
exhaustion.  145 
 146 
Metabolic substrate availability and exhaustion: Goldilocks and the 3 147 
substrates 148 
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Emerging evidence has implicated several metabolic pathways as important 149 
players in the development of T cell exhaustion. However it should be noted that, 150 
as with their contribution to T cell differentiation more broadly, their respective 151 
roles are actually integrated, with changes in one influencing many others.  152 
 153 
(FIGURE 2: metabolic substrates and T cell exhaustion) 154 
 155 
Hypoxia and exhaustion 156 
Both metabolic and effector dysfunction of TIL is clearly driven by and restricted 157 
to the tumour microenvironment19,20,22,23. Local metabolic substrate availability 158 
is an important factor shaping exhaustion and may also explain some of the 159 
variation in metabolic parameters between exhaustion models (Fig. 2a). 160 
It has long been known that the tumour microenvironment is hypoxic and that 161 
this favours tumour growth24. However, recent work has revealed the 162 
importance of hypoxia in driving the metabolic dysfunction of exhaustion. The 163 
tumour suppressor gene Vhl does not interact with Hif (hypoxia inducible factor) 164 
subunits under hypoxic conditions, allowing Hif to translocate to the nucleus and 165 
mediate transcription of target genes. Genetic deletion of Vhl unleashed Hif 166 
activity during persistent T cell responses resulting in fatal immunopathology 167 
during chronic LCMV infection but improving survival in an experimental 168 
melanoma model as T cells maintained effector function instead of exhausting25. 169 
This work further supports the prevailing theory that exhaustion has evolved as 170 
a mechanism by which chronic infection is ‘tolerated’ rather than risk fatal injury 171 
during an attempt to clear it17. It also highlights the importance of the 172 
hypoxia/Vhl/Hif pathway in controlling T cell effector function during persistent 173 
antigen stimulation. A metabolomic study of Vhl-deficient murine CD8+ T cells 174 
(with consequent high levels of Hif activity) subsequently identified S-2-175 
hydroxyglutarate (S2HG) as a key immunometabolite controlling persistent CTL 176 
activity in both immunisation and tumour models26. S2HG levels are increased by 177 
TCR stimulation in a Hif-dependent fashion but may also be influenced by other 178 
metabolic pathways including glutaminolysis promoting both effector 179 
differentiation and persistence26. It also appears that the contribution of hypoxic 180 
Vhl/Hif signalling to exhaustion is distinct from the contribution of classic 181 
inhibitory receptors. In the absence of Vhl (P14 Vhl-/- in the LCMV-cl13 model), 182 
classic inhibitory receptors such as LAG3 and PD1 were still induced during 183 
chronic infection but exhaustion did not develop, resulting in lethal 184 
immunopathology driven by an aggressive CD8+ CTL response. 185 
Hypoxia is a constant presence in conditions of rapid T cell infiltration, 186 
proliferation and activation whether this is in the TME, virally infected tissue or 187 
in the context of autoinflammatory disease. It is clear that the T cell metabolic 188 
response to this hypoxic microenvironment is an important determinant of its 189 
ability to sustain an effector response and consequently of disease outcome. 190 
However, the exact impact of hypoxia on T cell effector function remains unclear 191 
with some studies suggesting that limiting Hif expression (by knockdown rather 192 
than genetic deletion) can improve rather than attenuate effector capacity27.   193 
 194 
Glucose and exhaustion 195 
T cell activation is characterised by aerobic glycolysis, the switch away from 196 
OXPHOS despite the presence of sufficient oxygen to maintain it13. However, a 197 
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lack of glucose availability in – or a lack of uptake from - the microenvironment 198 
does have important consequences for persistence of T cell effector function 199 
(Fig. 2b). Some studies have suggested that limiting glycolysis can favour 200 
OXPHOS-mediated memory formation and enhanced persistent effector 201 
function28, although others have demonstrated a need for ongoing glycolysis to 202 
maintain effector function29. This apparent discrepancy reflects a need for 203 
glycolysis-driven effector function to be counterbalanced by a concurrent need 204 
for memory formation, driven by alternative metabolic pathways such as Hif, 205 
FAO and OXPHOS. At least some glycolysis is clearly required for initial T cell 206 
activation and for the development and maintenance of proliferation and effector 207 
function2,13. Similarly, even in the setting of enforced constitutive glycolysis 208 
(achieved through conditional deletion of Vhl) a long-lived memory population 209 
does develop, albeit skewed towards an effector-memory phenotype29. A 210 
balanced contribution of both effector-associated glycolysis and memory-211 
promoting metabolism such as FAO and OXPHOS is required for optimal T cell-212 
mediated control of pathogen or tumour30. Skewing the response too far in either 213 
direction could hamper persistent effector function. 214 
Texh cells do show an early reduction in GLUT1-mediated glucose uptake and 215 
early gene expression profiles consistent with glucose deprivation18,19,31. When 216 
TIL or Texh cells from chronic LCMV infection were exposed to conditions of 217 
glucose deprivation, they showed attenuation of both TCR and NFAT signalling 218 
with associated defects in Ca2+ flux, akin to those charcterising T cell anergy31,32. 219 
Altered levels of the glycolytic metabolite phosphoenolpyruvate (PEP)31 in Texh 220 
also contribute to the observed metabolic and effector dysfunction and do not 221 
simply reflect secondary changes in metabolism. Glycolysis-induced PEP 222 
accumulation was identified as necessary to sustain both Ca2+ and NFAT 223 
signalling – and hence effector function - following TCR activation, with a loss of 224 
IFN- and CD40L expression when it was suppressed31.  225 
This same study also reminds us that cells are continually competing for 226 
metabolic substrates in their local microenvironment – and it is not just a T cells 227 
ability to take up and use a substrate that determines metabolic fitness, the 228 
competing ability of neighbouring cells may be just as important. Overexpression 229 
of the enzyme hexokinase-2 in tumour cells increased their rate of glycolysis 230 
with evidence of glucose deprivation developing in TILs as a consequence31. This 231 
competition for substrate has been elegantly demonstrated in the TME, where 232 
tumour cell-driven changes in the availability of glucose were reflected in a 233 
reduction in TIL effector capacity20. A reduction in tumour cell glycolysis may at 234 
least in part explain the reversal of TIL exhaustion and the success of 235 
‘checkpoint’ inhibitory receptor blockade20. The degree to which such 236 
competition for substrate contributes to exhaustion in the context of either 237 
chronic infection or autoimmune responses is less clear, although is very likely to 238 
play a role.  239 
 240 
Amino acids, survival and effector differentiation 241 
Enhanced T cell survival in an exhausting tumour microenvironment has also 242 
been shown through increased uptake and metabolism of L-Arginine, that is 243 
usually specifically depleted during T cell activation33. Increased L-Arginine 244 
correlated with improved T cell survival with differentiation skewed towards the 245 
replicative, CCR7+ central memory (Tcm) phenotype (Fig. 2c). Once again, 246 
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availability of the metabolic substrate controlled the response as restoring 247 
depleted L-Arginine levels improved cytotoxic capacity both in vitro and in 248 
vivo33. Once again, enhanced memory differentiation was associated with 249 
attenuation of effector function, in this case a reduction in IFN- production 250 
(although, consistent with memory differentiation, equivalent levels were 251 
produced on secondary restimulation)33. Cellular uptake of other amino acids 252 
(AA), including leucine34 and glutamine35 via the AA transporters slc7a5 and 253 
ASCT2 respectively, are important for initiation, maintenance and integration of 254 
TCR signals with downstream metabolic sensors mTOR. They have not as yet 255 
been investigated in the context of exhaustion but their expression and AA 256 
availability is likely to also play a role. The critical AA transporter CD98, a 257 
downstream target of the metabolic regulator c-Myc36 and a heterodimer 258 
incorporating slc7a5, does show elevated expression on memory but not 259 
exhausted CD8+ T cells during chronic infection37.   260 
 261 
Together, these data make it clear that competition for metabolic substrate 262 
within the local microenvironment is a critical factor influencing the balance of 263 
effector function and T cell persistence during exhaustion19,20,31.  264 
 265 
Metabolic exhaustion in different models: the same but different 266 
The majority of studies to date consistently demonstrate metabolic dysfunction 267 
preceding exhaustion in different contexts. Furthermore, the observations are 268 
not restricted to murine models of disease. TIL from human cancer have been 269 
shown to have a similarly dysfunctional metabolic phenotype19,38 while human 270 
CD8+ T cells specific for chronic persistent (HBV)39,40 but not acute (influenza)40 271 
or recurrent virus infections (CMV)39 have been shown to have similar 272 
limitations in glucose uptake and mitochondrial biomass. 273 
However, while bioenergetic changes of Texh appear broadly similar in both TIL 274 
and chronic viral models, there are also differences. Whereas Texh in chronic 275 
LCMV infection showed greater mitochondrial biomass and increased ROS 276 
production18, TILs showed a reduction in both19.  The apparent contribution of 277 
PD1 signalling to metabolic dysfunction was also different in the two contexts. 278 
Early metabolic dysfunction of Texh in LCMVcl13 infection responded to either 279 
genetic deletion of PD1 (adoptive transfer of transgenic Pdcd1-/- LCMV-specific 280 
P14 T cells) or to PDL1 blockade18,19. However, mitochondrial biomass was not 281 
substantially altered by PD1 blockade in TILs, even though the blockade resulted 282 
in effective tumour regression19.  283 
Sampling of T cells at different stages of exhaustion (a dynamic process reflecting 284 
a continuum of dysfunction41) and from microenvironments comprising different 285 
substrate availabilities may explain at least some of the variance observed. 286 
However, other factors may also contribute. Texh cells are known to be 287 
heterogeneous, with two principal subsets defined by both their level of PD1 288 
expression and reciprocal expression of the transcription factors Tbet and 289 
Eomes30. The TbethiEomesloPD1int subset show greatest proliferative potential, 290 
are the lineage precursors of their more cytotoxic TbetloEomeshiPD1hi 291 
counterparts and are the dominant subset responding to PD1-PDL1 blockade42. 292 
In LCMV, the TbetloEomeshiPD1hi subset was shown to have more severe 293 
metabolic dysfunction consistent with its ‘terminally exhausted’ phenotype. The 294 
distribution of these subsets amongst TIL is not currently clear 19,38 but the lack 295 
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of .a metabolic response to PD1 blockade19 suggests they are likely to be 296 
enriched for ‘terminally exhausted’ cells. The observation that adoptive transfer 297 
of TIL into an acute viral infection setting (VV-OVA) fails to restore their 298 
function, is consistent with it19. Despite this, a bioenergetic revival following PD1 299 
blockade, such as is seen in chronic infection18, may still occur in tumour models 300 
and contribute to revival of tumoricidal function. However, it may be occurring 301 
out with the tumour microenvironment in less terminally-exhausted T cells and 302 
consequently not be visible within it. 303 
  304 
Exhaustion is a spectrum rather than a binary state15 and both its extent and the 305 
nature of its induction may differ depending on the context. TILs show an 306 
exhausted phenotype only within the tumour microenvironment, remaining fully 307 
functional in the periphery of tumour-bearing mice15,19 or in human cancer22,38. 308 
Indeed, TIL metabolic dysfunction could not be reproduced on co-culture of CD8+ 309 
T cells with isolated tumour cells in vitro19 indicating an important and complex 310 
role of the microenvironment in its induction. By contrast, exhaustion is 311 
apparent between different mice rather than between different anatomical 312 
locations in the same mouse43. Those receiving the clone 13 strain of LCMV 313 
develop chronic infection and exhaustion, while those receiving the highly 314 
related Armstrong strain have robust memory differentiation following an acute, 315 
self-terminating infection.  316 
It is clear that T cell bioenergetics vary markedly between different tissues 317 
during infection18,19 and also between distinct tumour models19, highlighting the 318 
importance of context for their development and maintenance. Given evidence 319 
demonstrating the importance of local microenvironmental signals, substrate 320 
availability and the phenotype of neighbouring cell types (both immune and 321 
stromal), it is less surprising that, in different contexts, T cells come to be 322 
exhausted by different paths. 323 
 324 
Early T cell metabolism may control exhaustion, but what controls early T 325 
cell metabolism? 326 
Multiple lines of evidence support the assertion that metabolic pathways control 327 
the development of T cell exhaustion, although exact in vivo mechanisms remain 328 
to be fully elucidated. But what signals control those metabolic pathways early 329 
after activation? A series of elegant studies have now identified major signalling 330 
pathways controlling the balance between effector and memory differentiation. 331 
More recently, these pathways have been investigated in both TIL and chronic 332 
infection models of T cell exhaustion, indicating an important role there also. 333 
  334 
During T cell activation and proliferation the intracellular serine/threonine 335 
kinase mTOR (mechanistic target of rapamycin) integrates diverse 336 
environmental signals including those derived from nutrient, cytokine and TCR 337 
signalling pathways44. Effector differentiation is favoured by TCR-triggered 338 
PI3K/Akt activity, driving mTOR-dependent14 inactivation of the transcription 339 
factor FOXO145. FOXO1 serves to repress effector function and promote memory 340 
formation by increasing expression of the transcription factor Eomesodermin 341 
and by concurrently repressing Tbet46. In the presence of TCR signals, such 342 
FOXO1 inactivation tips this balance towards Tbet-mediated effector 343 
differentiation (Fig. 3). It is also clear that many signals feed into this complex 344 
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junction, including those dependent on the local availability of metabolic 345 
substrates considered above, including hypoxia, glucose, immunometabolites 346 
such as S2HG, PEP and amino acids such as L-arginine25,29,31,33. 347 
 348 
FIGURE 3: metabolism integrates inhibitory and TCR signalling in 349 
exhaustion 350 
 351 
Inhibitory receptor control: PD1 and T cell metabolism 352 
It is now becoming apparent that early inhibitory receptor signalling in activated 353 
T cells can modulate T cell metabolism to influence the later development of 354 
exhaustion. It has long been known that T cell exhaustion is driven by high levels 355 
of sustained TCR signalling41,47. However recent work has shown that, despite 356 
ongoing antigen exposure and TCR triggering, downstream PI3K/AKT/mTOR 357 
signalling in exhaustion is not similarly sustained18,48 – in other words, persistent 358 
antigen may drive exhaustion but this does not correspond to persistent 359 
downstream TCR signals. PD1 expression is induced on antigen-stimulated cells 360 
by TCR signals through NFATc49-51. However, PD1 ligation is capable of 361 
‘desensitising’ the TCR signal, allowing a degree of ongoing nuclear FOXO1 362 
activity that in turn sustains both further PD1 expression and ongoing TCR 363 
desensitisation48. This establishes a self-reinforcing cycle that restrains 364 
development of full effector function with an associated switch away from 365 
aerobic glycolytic metabolism48,52.  366 
These data suggest that persistent PD1 signalling actually facilitates T cell 367 
survival in the face of persistent antigenic stimulus. By desensitising TCR signals, 368 
PD1 may actually serve to maintain a degree of bioenergetic fitness in the face of 369 
persistent antigen exposure. We have seen that exhausted T cells do show 370 
evidence of metabolic dysfunction18,19. However, without persistent PD1 signals 371 
this could be much worse. PD1 can therefore act to facilitate an ongoing, if 372 
attenuated, T cell response in the context of persistent TCR activation48. This 373 
system is complex, however – genetic deletion of PD1 can counterintuitively 374 
allow the later accumulation of ‘terminally exhausted’ cells (Pdcd1-/-)53. However, 375 
the details of how PD1 facilitates survival with attenuated function remain 376 
unclear and its effects are likely to vary with the time post stimulation (early 377 
versus late, see discussion of PGC1a below). 378 
This role for PD1 in T cell differentiation also makes evolutionary sense. It is 379 
likely that exhaustion has evolved as a means of carefully balancing control of 380 
chronic infection with the risk of causing damaging immunopathology17. During 381 
acute T cell activation, a feedback loop is established whereby strong TCR signals 382 
drive Akt -mediated cytotoxicity (Fig. 3) but also drive PD1 expression, limiting 383 
that TCR signalling. Should TCR signals persist, they will be desensitised by PD1, 384 
allowing preservation of bioenergetic fitness sufficient to sustain a longer-term, 385 
albeit more restrained, T cell response.  386 
These new insights into metabolic control of T cell exhaustion have important 387 
implications for the design of therapies aimed at its modulation. This schema 388 
may also initially seem at odds with observations that PD1 blockade can promote 389 
restoration of cytotoxicity in both TILs16 and in chronic viral infection54. 390 
However, PD1-driven desensitisation of TCR signals and preservation of some 391 
metabolic fitness serves to keep T cells in the fight – the response to persistent 392 
antigen is, after all, more of a marathon than a sprint. Reversing exhaustion 393 
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through inhibitory receptor blockade shows much promise as a therapeutic 394 
approach in chronic infection or cancer23,54,55. PD1 blockade can clearly induce 395 
increased cytotoxicity of exhausted CD8+ T cells.  However, if this occurs through 396 
promoting ‘terminal’ differentiation of more cytotoxic TbetloEomeshiPD1hi cells at 397 
the expense of a more durable and metabolically-fit TbethiEomesloPD1int 398 
population30,53, such therapy could effectively undercut the immune systems 399 
capacity to maintain an ongoing response. The predicted result would be 400 
eradication of the targeted antigen (whether tumour or virus) in some cases 401 
where induced cytoxicity was sufficient, but perhaps a ‘deeper’ state of 402 
subsequent exhaustion where it isn’t and residual metabolic fitness was lost 403 
through inhibitory receptor blockade. 404 
 405 
What is less clear at this stage is exactly how this perpetuating cycle is 406 
established in the first place. While the microenvironmental signals discussed 407 
above are important, costimulatory signalling is very likely to also contribute. A 408 
lack of costimulatory signals during TCR triggering results in a hyporesponsive 409 
state termed anergy32. Costimulatory signals, such as those received through 410 
CD28 binding56,57 or cytokines such as IL-2 (ref 58), are critical for upregulation of 411 
glucose, AA transporters and the FAO regulator CPT1a that facilitate the 412 
metabolic switch underlying T cell activation13,57. A failure of such initial 413 
costimulation results in comparative metabolic quiescence and anergy59. 414 
Exhaustion is distinct from anergy: T cells have received sufficient stimulatory 415 
signals to activate, but they continue to receive them and become dysfunctional. 416 
However, inadequate costimulation (rather than absent costimulation as in 417 
anergy) also contributes to development of exhaustion60,61 and is likely to 418 
promote the early PD1-driven cycle of bioenergetic compromise promoting later 419 
exhaustion (Fig. 3). 420 
 421 
Other inhibitory receptors 422 
Just as the precise nature of metabolic dysfunction of exhausted cells appears 423 
different in different contexts (see above), so the mechanism by which it 424 
develops may also be distinct. A range of coinhibitory receptors are highly 425 
expressed on exhausted T cells and play distinct but synergistic roles in driving 426 
that phenotype49. Mitochondrial dysfunction of TILs is apparent in the tumour 427 
microenvironment of mutliple mouse models19,20,31 and in human cancers19,38. 428 
However, the degree of metabolic dysfunction does not directly parallel the 429 
concurrent level of inhibitory receptor expression19,26 in each context. 430 
Exhaustion can clearly develop in the absence of specific inhibitory receptor 431 
expression18,53 and inhibitory receptor expression can be present without the 432 
development of exhaustion, for example where Vhl/Hif signals are absent25. 433 
Further, whereas metabolic changes are important drivers of exhaustion early 434 
during TCR signalling, exhaustion can be at least partially reversed at later stages 435 
with increased cytotoxicity despite no clear modulation of metabolism18,19. 436 
Together, these data suggest that multiple, redundant signals must contribute to 437 
the development of exhaustion and its associated metabolic dysfunction. The 438 
summated input from these cell surface and local environmental signals 439 
contribute to the resulting degree of exhaustion.  440 
 441 
mTOR and metabolism in exhaustion 442 
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During T cell activation mTOR acts to integrate multiple signals including from 443 
metabolic, cytokine and TCR signalling pathways44. Perhaps unsurprisingly, 444 
mTOR activity has therefore been shown to have a central role in T cell 445 
metabolism and, more recently, in exhaustion. It was, however, initially a 446 
surprise when the immunosuppressive drug rapamycin, an inhibitor of mTOR, 447 
was found to promote T cell memory differentiation and the associated switch 448 
away from aerobic glycolysis towards FAO metabolism8,14. It has been used for 449 
some time as an immunosuppressive agent capable of limiting TCR-driven 450 
activation and proliferation. However, mTOR has since been shown to directly 451 
promote phosphorylation and inactivation of FOXO1, promoting effector 452 
differentiation through downstream Tbet-mediated effects45,46,62,63 .  453 
Early mTOR blockade in the LCMV-cl13 chronic viral infection model also 454 
modestly improved mitochondrial fitness of exhausted cells (depolarisation and 455 
size18) suggesting that chronic mTOR signals downstream of the TCR can 456 
contribute to the metabolic changes of exhaustion, even if TCR signals are 457 
downtuned by PD1. It has been observed that blocking mTOR actually impairs 458 
TIL response to PD1 blockade, suggesting that ongoing mTOR signalling to at 459 
least some degree may be needed to preserve effector function18,19. 460 
 461 
The evidence for mTOR involvement in the metabolic phenotype of exhaustion 462 
highlights the complex, dynamic balance between ‘terminal’ effector function and 463 
T cell persistence. While mTOR signalling may in part drive the cell away from 464 
mitochondrial metabolism toward anaerobic glycolysis, these changes are a 465 
necessary part of effector differentiation. Both are required for adequate ongoing 466 
T cell responses to persistent antigen and the degree to which either path is 467 
inhibited impacts on the resulting phenotype30.  468 
 469 
FOXO signals and exhaustion: death, survival and metabolism 470 
FOXO transcription factors integrate signals from growth factors, substrate 471 
availability and inflammation and in turn regulate cellular growth, differentiation 472 
and metabolism64. The balance of FOXO signalling is clearly important in 473 
directing CD4+ regulatory T cell differentiation65,66, however this balance also 474 
plays an important cell-intrinsic role in CD8+ T cell differentiation and in 475 
directing metabolic dysfunction of exhaustion. FOXOs 1 and 3 are expressed in T 476 
cells64. FOXO1 activity promotes T cell survival and persistence67,68 while FOXO3 477 
activity limits survival through pro-apoptotic effects mediated by Bim and 478 
PUMA69-71. Ablating FOXO3 activity (Foxo3-/- CD8+ T cells) restricts the 479 
contraction phase post-stimulation allowing greater persistence of effector CD8+  480 
T cells72, facilitating clearance of chronic LCMV infection73 and control of HIV in 481 
humans74. By contrast, FOXO1 signalling can maintain a pluripotent stem cell 482 
phenotype75 and is required for differentiation of effector CD8+ T cells into a 483 
functional memory subset76 through its downstream modulation of the 484 
transcription factors Tbet and Eomes46. It is therefore likely that the balance of 485 
FOXO signalling following TCR signals will determine the balance of effector fate 486 
and cellular persistence during chronic antigen exposure.  487 
However, the balance of FOXO-driven regulation is complex64 and a complete 488 
picture of its contribution to the metabolic dysfunction of exhaustion has yet to 489 
emerge with several apparent contradictions persisting. For example, the role of 490 
FOXO3 in promoting apoptosis and effector differentiation is at odds with its 491 
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apparent ability to maintain PGC1a expression and metabolic fitness (described 492 
below). Similarly, despite its role in promoting stem cell-like persistence, FOXO1 493 
also appears to be necessary for differentiation of the terminally exhausted 494 
TbetloEomeshiPD1hi subset48. These apparent discrepancies may reflect the 495 
complex integration by FOXOs of multiple other pathways including hypoxic 496 
signalling77, metabolic pathways78 and nutrient availability79. A future challenge 497 
will be to fully understand the complex role of these transcription factors in 498 
regulating metabolism during exhaustion.  499 
 500 
PGC1a: regulation at the heart of metabolic exhaustion? 501 
The ability to sustain energy production during rapid cellular proliferation 502 
requires mitochondrial biogenesis and the induction of gene expression 503 
programmes regulating substrate uptake and use. This process is controlled by 504 
the transcriptional coactivator PGC1a80 through control of both nuclear 505 
respiratory factors (Nrf) and mitochondrial transcription factor A (Tfam)81. It is 506 
now clear that PGC1a is central to the metabolic dysfunction of exhaustion in 507 
both LCMVand tumour models. PGC1a shows reduced levels of expression in 508 
both TIL19 and Texh in the LCMV model18, while its overexpression limits 509 
mitochondrial dysfunction 18,19, facilitating the emergence of polyfunctional CD8 510 
T cells18 that drive tumour infiltration and regression19.  511 
The FOXO family of transcription factors  - both FOXO119,82 and FOXO319,83 - have 512 
each been shown to promote PGC1a expression. Conversely, PGC1a expression is 513 
repressed by TCR-driven Akt signalling82 which in turn phosphorylates and 514 
inactivates FOXOs 1 and 381. Therefore persistent antigen/TCR signalling may 515 
serve to maintain Akt signalling and promote effector differentiation, but 516 
metabolic fitness will also be curtailed as FOXO-driven PGC1a expression is 517 
restricted (Fig. 3).  518 
It remains unclear, however, exactly how complex signals from multiple 519 
inhibitory receptors including PD1 are integrated to modulate PGC1a levels and 520 
whether this is the only or the most important transcription factor modulating 521 
early metabolic fitness. Absence of PD1 from the onset of a T cell response 522 
(through genetic deletion, Pdcd1-/-) facilitates a later expansion of exhausted 523 
cells in the absence of inhibitory signals restraining cytotoxicity and terminal 524 
differentiation53. This demonstrates that PD1 is not essential for the 525 
development of exhaustion and its expression at certain points may even limit its 526 
development. Genetic ablation of PD1 also results in higher expression of 527 
PGC1a18 suggesting that, if PD1 is acting to preserve a degree of early 528 
bioenergetic fitness and to facilitate later survival despite ongoing stimulation, it 529 
is unlikely to be doing so through PGC1a. Other data showing delayed tumour 530 
progression after PD-1 blockade in the absence of metabolic changes in TIL also 531 
suggest additional mechanisms27. Further studies will be required to clarify the 532 
complexity of these signalling events. 533 
 534 
Autoimmune disease, metabolism and exhaustion 535 
T cell exhaustion regulates cellular immunity during the response to persistent 536 
antigenic stimulation, whether that is during chronic viral infection or in the 537 
tumour microenvironment. Exhaustion has also been inversely associated with a 538 
relapsing course of autoinflammatory disease, another instance of immune 539 
reactivity to persistent antigen (in this case, ‘self’). A transcriptional signature 540 
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specific for exhaustion correlates with a reduced rate of relapse in multiple 541 
diseases61 and features of T cell exhaustion correlate with favourable response 542 
during immunotherapy of type 1 diabetes84. Such observations are consistent 543 
with the evolution of exhaustion as a mechanism to limit immunopathology in 544 
the face of persistent TCR stimulation17,41.  A broadly similar phenotype of 545 
exhaustion is apparent in the distinct contexts of chronic viral infection and the 546 
tumour microenvironment. These broad similarities are accompanied by specific 547 
differences, too, likely driven by distinct signals received in each context. It is 548 
likely that immunometabolism also plays a key role in control of effector, 549 
persistent or exhausted T cell responses in autoimmunity.  550 
 551 
It is clear that metabolic ‘switches’ are not only important for the initiation of T 552 
cell activation13 but are also responsible for controlling an ongoing balance of 553 
effector/memory differentiation and exhaustion18,19. Many studies have sought 554 
to directly compare measures of metabolic fitness in autoinflammatory disease, 555 
typically making comparison with uninflamed, healthy control tissues and 556 
sampling cells during or after active autoinflammation and immunosuppressive 557 
therapy85. In this context it is unsurprising to find altered metabolism as a 558 
secondary consequence of immune activation or therapeutic modulation – 559 
indeed it would be surprising not to find it. This highlights the need for 560 
appropriate control for variable proliferation and immune activation in models 561 
and assays of immunometabolism, such as those used during LCMV models 562 
(where adoptive transfer of small numbers of transgenic, LCMV-specific P14 T 563 
cells facilitates their direct comparison with host cells in an equivalent 564 
context18,53). Evidence to support a primary role of exhaustion-associated 565 
metabolic dysfunction in autoinflammatory disease is more limited. 566 
 567 
Several recent genetic studies have, however, implicated exhaustion-associated 568 
metabolic pathways in the onset and progression of multiple autoimmune 569 
phenotypes. Perhaps the most striking example is the recurrent association of a 570 
variant allele in neutrophil cytosolic factor 1 (Ncf1) with onset or severity of 571 
multiple autoinflammatory diseases86. Ncf1 is a necessary for activation of 572 
NADPH oxidase and consequent production of superoxide during the respiratory 573 
burst. Reduction in ROS levels in the presence of a mutant allele leads to 574 
increased severity and relapse in mouse models of multiple sclerosis  and 575 
rheumatoid arthritis86,87 and shows association with multiple human 576 
autoimmune diseases86. Redox signalling can be controlled by PD1 signalling in T 577 
cells88 and ROS generation has been implicated in the metabolic dysfunction of 578 
exhaustion18,19. However, a direct link between NCF1 function and exhaustion 579 
remains to be tested.  580 
The process of T cell exhaustion has thus far been associated with the 581 
progression rather than onset of autoinflammatory disease61,84, although 582 
exhaustion-associated inhibitory receptors have also been linked to broken 583 
tolerance17. A genome-wide association study of clinical outcome has identified a 584 
variant allele in FOXO3 associated with disease progression (but not 585 
susceptibility) in Crohn’s disease, rheumatoid arthritis and malaria infection89. 586 
Alongside the association of T cell exhaustion with outcome in Crohn’s disease61 587 
this suggests a possible role for FOXO3-driven metabolic control of T cell 588 
exhaustion in autoinflammatory disease. However, FOXO3 the Crohn’s associated 589 
 13 
variant allele has not as yet been functionally tested in T cells and a monocyte-590 
intrinsic signalling pathway directing TGF- and TNF production is at least partly 591 
responsible for the association90.  592 
 593 
Summary 594 
During T cell activation changes in cellular metabolism are inevitably required to 595 
sustain the rapid changes in cell function. Increasing evidence suggests that 596 
metabolic changes do not simply react to changes in T cell differentiation but 597 
drive them. It is now apparent that the integration of complex early signals from 598 
a cells microenvironment is critical both for initiating activation and for 599 
regulating the nature of ‘downstream’ differentiation. These signals direct 600 
phenotypes of effector function and memory development, but also of T cell 601 
exhaustion during chronic antigen exposure. 602 
In both chronic infection and tumour models where exhaustion is apparent, 603 
metabolic changes in T cells occurred rapidly, prior to the emergence of 604 
exhaustion per se, and were maintained into later stages. Multiple observations 605 
therefore confirm a prominent role for cellular metabolism in ‘upstream’ control 606 
of exhaustion rather than simply reflecting changes secondary to its 607 
development.  608 
A wealth of evidence also indicates that signalling pathways promoting cellular 609 
persistence/survival can be dissociated from those controlling effector function. 610 
Signals promoting aerobic glycolysis during activation may enhance effector 611 
differentiation but this may be at the expense of memory potential. Conversely, 612 
the use of alternative pathways such as lipid metabolism at the expense of 613 
aerobic glycolysis may do the opposite. However, both processes are required in 614 
parallel to appropriately mount an effective, durable T cell response to persistent 615 
antigen30. As such, the metabolic balance between effector function and 616 
persistence represents another example of the ‘Goldilocks’ principle, in which 617 
effector and memory differentiation must be neither too much nor too little, but 618 
‘just right’ in order to appropriately deal with infection without the development 619 
of immunopathology. Future challenges will include quantifying the extent to 620 
which each metabolic pathway contributes to T cell function, how each is 621 
controlled and how we might harness that knowledge to modulate metabolism 622 
and hence immunity. To achieve this, our understanding of T cell metabolism 623 
during human disease will have to catch up with the advances driven by 624 
informative mouse models of cancer and infection. However, modulating 625 
immunometabolism shows promise as a means of controlling chronic T cell 626 
responses in infection, cancer and autoinflammatory disease. 627 
 628 
 629 
 630 
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